Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AV 001-Vasomune Therapeutics (Primary)
  • Indications Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; First in man
  • Sponsors Vasomune Therapeutics

    • Most Recent Events

    • 22 May 2024 Results assessing safety and pharmacokinetics of AV001 in Healthy Subjects for the Treatment of Acute Respiratory Distress Syndrome presented at the 120th International Conference of the American Thoracic Society
    • 06 May 2024 According to a Vasomune Therapeutics media release, data from this study will be presented at 2024 American Thoracic Society (ATS) International Conference
    • 25 Mar 2021 Top-line results presented in a Vasomune Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top